Cresset Asset Management’s BioNTech BNTX Stock Holding History

Cresset Asset Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$253K	Buy	2,722 +6	+0.2%	+$565	﹤0.01%	1464
2026 Q1	$241K	Sell	2,716 -30	-1%	-$3.08K	﹤0.01%	1383
2025 Q4	$261K	Buy	2,746 +30	+1%	+$3.02K	﹤0.01%	1363
2025 Q3	$268K	Hold	2,716	–	–	﹤0.01%	1292
2025 Q2	$289K	Sell	2,716 -2,048	-43%	-$207K	﹤0.01%	1146
2025 Q1	$434K	Sell	4,764 -1,035	-18%	-$116K	﹤0.01%	1140
2024 Q4	$661K	Sell	5,799 -532	-8%	-$60.7K	﹤0.01%	967
2024 Q3	$752K	Sell	6,331 -5,496	-46%	-$505K	﹤0.01%	1304
2024 Q2	$950K	Buy	11,827 +7,089	+150%	+$648K	﹤0.01%	1096
2024 Q1	$437K	Buy	4,738 +155	+3%	+$14.9K	﹤0.01%	1401
2023 Q4	$484K	Buy	+4,583	New	+$462K	﹤0.01%	1249

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Cresset Asset Management's BNTX Position: Q2 2026 in Review

Cresset Asset Management increased its BioNTech (BNTX) stake by 0.22% in Q2 2026, buying an estimated $565 and bringing the position to 2,722 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #1464.

Cresset Asset Management first reported a position in BNTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $950K in Q2 2024. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Cresset Asset Management held 2,722 shares of BioNTech worth $253K as of Q2 2026.
Cresset Asset Management bought 6 BioNTech shares in Q2 2026, an estimated $565.
BioNTech made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1464 holding.
Cresset Asset Management first reported a position in BioNTech in Q4 2023 and has held it in 11 quarters since.
Cresset Asset Management's BioNTech position peaked at $950K in Q2 2024.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.